Company intelligence / Profile preview

Innosphere Engineering

Houston, TX, USA

Ownership: Private
Development stage: Other

Overview

In first clinical trials, Novostim system reduced ADHD symptom severity by 43% after ten sessions, with maintained improvements weeks after treatment; current pivotal trial underway at major US pediatric research hospitals, evaluating safety/efficacy of Novostim 2 (tRNS device) in children aged 7-12 years

Therapeutic areas: Psychiatry
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

UTHealth HoustonMayo ClinicBoston Children's HospitalBaylor College of MedicineTexas Children's Hospital

Beyond the preview

Go deeper on Innosphere Engineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innosphere Engineering.

Explore the full profile